Modulators of redox metabolism in head and neck cancer

Xiaofei Chen, Jade Mims, Xiumei Huang, Naveen Singh, Edward Motea, Sarah M. Planchon, Muhammad S Beg, Allen W. Tsang, Mercedes Porosnicu, Melissa L. Kemp, David A Boothman, Cristina M. Furdui

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Significance: Head and neck squamous cell cancer (HNSCC) is a complex disease characterized by high genetic and metabolic heterogeneity. Radiation therapy (RT) alone or combined with systemic chemotherapy is widely used for treatment of HNSCC as definitive treatment or as adjuvant treatment after surgery. Antibodies against epidermal growth factor receptor are used in definitive or palliative treatment. Recent Advances: Emerging targeted therapies against other proteins of interest as well as programmed cell death protein 1 and programmed death-ligand 1 immunotherapies are being explored in clinical trials. Critical Issues: The disease heterogeneity, invasiveness, and resistance to standard of care RT or chemoradiation therapy continue to constitute significant roadblocks for treatment and patients' quality of life (QOL) despite improvements in treatment modality and the emergence of new therapies over the past two decades. Future Directions: As reviewed here, alterations in redox metabolism occur at all stages of HNSCC management, providing opportunities for improved prevention, early detection, response to therapies, and QOL. Bioinformatics and computational systems biology approaches are key to integrate redox effects with multiomics data from cells and clinical specimens and to identify redox modifiers or modifiable target proteins to achieve improved clinical outcomes. Antioxid. Redox Signal.

Original languageEnglish (US)
Pages (from-to)1660-1690
Number of pages31
JournalAntioxidants and Redox Signaling
Volume29
Issue number16
DOIs
StatePublished - Dec 1 2018

Fingerprint

Head and Neck Neoplasms
Metabolism
Modulators
Oxidation-Reduction
Radiotherapy
Programmed Cell Death 1 Receptor
Squamous Cell Neoplasms
Chemotherapy
Therapeutics
Bioinformatics
Head
Epidermal Growth Factor Receptor
Surgery
Computational Biology
Proteins
Ligands
Quality of Life
Antibodies
Systems Biology
Genetic Heterogeneity

Keywords

  • Head and neck
  • HNSCC
  • Oxidative stress
  • Redox
  • Squamous cancer

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Molecular Biology
  • Clinical Biochemistry
  • Cell Biology

Cite this

Chen, X., Mims, J., Huang, X., Singh, N., Motea, E., Planchon, S. M., ... Furdui, C. M. (2018). Modulators of redox metabolism in head and neck cancer. Antioxidants and Redox Signaling, 29(16), 1660-1690. https://doi.org/10.1089/ars.2017.7423

Modulators of redox metabolism in head and neck cancer. / Chen, Xiaofei; Mims, Jade; Huang, Xiumei; Singh, Naveen; Motea, Edward; Planchon, Sarah M.; Beg, Muhammad S; Tsang, Allen W.; Porosnicu, Mercedes; Kemp, Melissa L.; Boothman, David A; Furdui, Cristina M.

In: Antioxidants and Redox Signaling, Vol. 29, No. 16, 01.12.2018, p. 1660-1690.

Research output: Contribution to journalReview article

Chen, X, Mims, J, Huang, X, Singh, N, Motea, E, Planchon, SM, Beg, MS, Tsang, AW, Porosnicu, M, Kemp, ML, Boothman, DA & Furdui, CM 2018, 'Modulators of redox metabolism in head and neck cancer', Antioxidants and Redox Signaling, vol. 29, no. 16, pp. 1660-1690. https://doi.org/10.1089/ars.2017.7423
Chen X, Mims J, Huang X, Singh N, Motea E, Planchon SM et al. Modulators of redox metabolism in head and neck cancer. Antioxidants and Redox Signaling. 2018 Dec 1;29(16):1660-1690. https://doi.org/10.1089/ars.2017.7423
Chen, Xiaofei ; Mims, Jade ; Huang, Xiumei ; Singh, Naveen ; Motea, Edward ; Planchon, Sarah M. ; Beg, Muhammad S ; Tsang, Allen W. ; Porosnicu, Mercedes ; Kemp, Melissa L. ; Boothman, David A ; Furdui, Cristina M. / Modulators of redox metabolism in head and neck cancer. In: Antioxidants and Redox Signaling. 2018 ; Vol. 29, No. 16. pp. 1660-1690.
@article{3c5deb774989496994c5695a88bddc6d,
title = "Modulators of redox metabolism in head and neck cancer",
abstract = "Significance: Head and neck squamous cell cancer (HNSCC) is a complex disease characterized by high genetic and metabolic heterogeneity. Radiation therapy (RT) alone or combined with systemic chemotherapy is widely used for treatment of HNSCC as definitive treatment or as adjuvant treatment after surgery. Antibodies against epidermal growth factor receptor are used in definitive or palliative treatment. Recent Advances: Emerging targeted therapies against other proteins of interest as well as programmed cell death protein 1 and programmed death-ligand 1 immunotherapies are being explored in clinical trials. Critical Issues: The disease heterogeneity, invasiveness, and resistance to standard of care RT or chemoradiation therapy continue to constitute significant roadblocks for treatment and patients' quality of life (QOL) despite improvements in treatment modality and the emergence of new therapies over the past two decades. Future Directions: As reviewed here, alterations in redox metabolism occur at all stages of HNSCC management, providing opportunities for improved prevention, early detection, response to therapies, and QOL. Bioinformatics and computational systems biology approaches are key to integrate redox effects with multiomics data from cells and clinical specimens and to identify redox modifiers or modifiable target proteins to achieve improved clinical outcomes. Antioxid. Redox Signal.",
keywords = "Head and neck, HNSCC, Oxidative stress, Redox, Squamous cancer",
author = "Xiaofei Chen and Jade Mims and Xiumei Huang and Naveen Singh and Edward Motea and Planchon, {Sarah M.} and Beg, {Muhammad S} and Tsang, {Allen W.} and Mercedes Porosnicu and Kemp, {Melissa L.} and Boothman, {David A} and Furdui, {Cristina M.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1089/ars.2017.7423",
language = "English (US)",
volume = "29",
pages = "1660--1690",
journal = "Antioxidants and Redox Signaling",
issn = "1523-0864",
publisher = "Mary Ann Liebert Inc.",
number = "16",

}

TY - JOUR

T1 - Modulators of redox metabolism in head and neck cancer

AU - Chen, Xiaofei

AU - Mims, Jade

AU - Huang, Xiumei

AU - Singh, Naveen

AU - Motea, Edward

AU - Planchon, Sarah M.

AU - Beg, Muhammad S

AU - Tsang, Allen W.

AU - Porosnicu, Mercedes

AU - Kemp, Melissa L.

AU - Boothman, David A

AU - Furdui, Cristina M.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Significance: Head and neck squamous cell cancer (HNSCC) is a complex disease characterized by high genetic and metabolic heterogeneity. Radiation therapy (RT) alone or combined with systemic chemotherapy is widely used for treatment of HNSCC as definitive treatment or as adjuvant treatment after surgery. Antibodies against epidermal growth factor receptor are used in definitive or palliative treatment. Recent Advances: Emerging targeted therapies against other proteins of interest as well as programmed cell death protein 1 and programmed death-ligand 1 immunotherapies are being explored in clinical trials. Critical Issues: The disease heterogeneity, invasiveness, and resistance to standard of care RT or chemoradiation therapy continue to constitute significant roadblocks for treatment and patients' quality of life (QOL) despite improvements in treatment modality and the emergence of new therapies over the past two decades. Future Directions: As reviewed here, alterations in redox metabolism occur at all stages of HNSCC management, providing opportunities for improved prevention, early detection, response to therapies, and QOL. Bioinformatics and computational systems biology approaches are key to integrate redox effects with multiomics data from cells and clinical specimens and to identify redox modifiers or modifiable target proteins to achieve improved clinical outcomes. Antioxid. Redox Signal.

AB - Significance: Head and neck squamous cell cancer (HNSCC) is a complex disease characterized by high genetic and metabolic heterogeneity. Radiation therapy (RT) alone or combined with systemic chemotherapy is widely used for treatment of HNSCC as definitive treatment or as adjuvant treatment after surgery. Antibodies against epidermal growth factor receptor are used in definitive or palliative treatment. Recent Advances: Emerging targeted therapies against other proteins of interest as well as programmed cell death protein 1 and programmed death-ligand 1 immunotherapies are being explored in clinical trials. Critical Issues: The disease heterogeneity, invasiveness, and resistance to standard of care RT or chemoradiation therapy continue to constitute significant roadblocks for treatment and patients' quality of life (QOL) despite improvements in treatment modality and the emergence of new therapies over the past two decades. Future Directions: As reviewed here, alterations in redox metabolism occur at all stages of HNSCC management, providing opportunities for improved prevention, early detection, response to therapies, and QOL. Bioinformatics and computational systems biology approaches are key to integrate redox effects with multiomics data from cells and clinical specimens and to identify redox modifiers or modifiable target proteins to achieve improved clinical outcomes. Antioxid. Redox Signal.

KW - Head and neck

KW - HNSCC

KW - Oxidative stress

KW - Redox

KW - Squamous cancer

UR - http://www.scopus.com/inward/record.url?scp=85055182254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055182254&partnerID=8YFLogxK

U2 - 10.1089/ars.2017.7423

DO - 10.1089/ars.2017.7423

M3 - Review article

VL - 29

SP - 1660

EP - 1690

JO - Antioxidants and Redox Signaling

JF - Antioxidants and Redox Signaling

SN - 1523-0864

IS - 16

ER -